SCHEMBL11041868

SCHEMBL11041868

O=C(Nc1ccncc1)c1cc[nH]n1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 2/20 0.51
NT5E P21589 1/20 0.51
JAK2 O60674 7/20 0.50
TYK2 P29597 6/20 0.50
JAK1 P23458 4/20 0.50
MDM2 Q00987 1/20 0.50
GAA P10253 1/20 0.50
CYP3A4 P08684 1/20 0.50
ROCK2 O75116 2/20 0.49
ROCK1 Q13464 2/20 0.49
XDH P47989 1/20 0.48
SLC22A12 Q96S37 1/20 0.48
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.46
NOD2 Q9HC29 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19748 0.84 KMT2A (0.61) KDM4EL3MBTL1KMT2AHTTALDH1A1
SCHEMBL23246023 0.83 NPC1 (0.53) KDM4EKMT2ANT5EXDHMEN1
SCHEMBL16692723 0.81 KMT2A (0.44) KDM4EL3MBTL1KMT2AGAACYP3A4
SCHEMBL168618 0.81 MEN1 (0.63) KDM4EKMT2AGAAMEN1MAPK1
SCHEMBL18027798 0.81 RAB9A (0.54) KDM4ECYP3A4HTTALDH1A1
SCHEMBL11039238 0.81 LMNA (0.58) KDM4EKMT2AMEN1ALDH1A1
SCHEMBL6002659 0.81 NPC1 (0.54) KMT2AMAPK1
SCHEMBL6532295 0.79 PTPN1 (0.53) KMT2AHTTALDH1A1
SCHEMBL23246003 0.79 GAA (0.63) KDM4EKMT2AGAAXDHMEN1
SCHEMBL23246004 0.78 RAB9A (0.66) KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262035-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2018-01-03 EP disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
US-9133128-B2 Pyrazole derivatives as cannabinoid receptor 1 antagonists RESEARCH TRIANGLE INSTITUTE (US) 2015-09-15 US disclosed
US-20140107157-A1 PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS RESEARCH TRIANGLE INSTITUTE (US) 2014-04-17 US disclosed
WO-2012174362-A1 PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS RESEARCH TRIANGLE INSTITUTE (US) 2012-12-20 WO disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107157-A1 PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS CNR1, CNR2, GPR119 KDM4E 3512/4885L3MBTL1 4496/4885KMT2A 4409/4885
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD KDM4E 1665/4885L3MBTL1 4014/4885KMT2A 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.